Scientists are working on cancer treatments that attack the disease’s ‘Holy Grail.’ Big pharma and biotechs have already invested more than $1 billion.
|05/15/2019||Posted by BusinessMediaguide.Com under General World News||
- A new technology could revolutionize how everything from Alzheimer’s disease to autoimmune diseases and cancer are treated.
- Cancer has become an early focus for the technology, called targeted protein degradation or PROTAC, because there are many well-known drivers of cancer that modern medicine hasn’t been able to reach.
- At least $1 billion has been invested in the space by big pharmaceutical companies like Novartis and GlaxoSmithKline and biotech startups alike, one expert estimates.
- Visit Business Insider’s home page for more stories.
An experimental technology that’s been under development for almost two decades could upend treatment for conditions ranging from read more >>>